Overview
This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 , Her-2 Negtive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Eligibility
Inclusion Criteria:
- Subjects voluntarily participate in the study and sign the informed consent form;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Expected survival time ≥ 12 weeks;
- Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma;
- No prior systemic anti-tumor treatment for unresectable locally advanced or metastatic disease;
- Has measurable or non-measurable (but assessable) disease;
- Patients with adequate cardiac, liver, renal function, etc.
Exclusion Criteria:
- Known history of allergy to any component of the study drug;
- Other second primary malignant neoplasm within 5 years;
- Significant cardiovascular and cerebrovascular disorders within 6 months before randomization;
- Haemorrhage requiring haemostatic treatment within 3 months prior to randomisation;
- Previous or current interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, etc;
- Previous treatment targeting CLDN18.2;
- Patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator.
